

Rafael Santana-Davila

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/24508/publications.pdf>

Version: 2024-02-01

20
papers

1,649
citations

933447

10
h-index

888059

17
g-index

20
all docs

20
docs citations

20
times ranked

2191
citing authors

#	ARTICLE	IF	CITATIONS
1	Performance status (<scp>PS</scp>) as a predictor of poor response to immune checkpoint inhibitors (<scp>ICI</scp>) in recurrent/metastatic head and neck cancer (<scp>RMHNSCC</scp>) patients. <i>Cancer Medicine</i> , 2022, 11, 4104-4111.	2.8	11
2	Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 289-298.	1.1	35
3	A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100416.	1.7	0
4	High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Journal of Palliative Medicine</i> , 2021, , .	1.1	0
5	Evorpaccept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. <i>Lancet Oncology</i> , The, 2021, 22, 1740-1751.	10.7	46
6	A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 837-845.	7.0	120
7	A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 170-177.	0.8	13
8	Duration of Targeted Therapy in Patients With Advanced Nonâ€“small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis. <i>Clinical Lung Cancer</i> , 2020, 21, 545-552.e1.	2.6	11
9	Nonâ€“Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1623-1640.	3.0	1,153
10	Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure. <i>Oncologist</i> , 2018, 23, 147-149.	3.7	2
11	The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer. <i>Future Oncology</i> , 2018, 14, 191-194.	2.4	5
12	Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies. <i>Head and Neck</i> , 2018, 40, 584-589.	2.0	13
13	A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 2740-2748.	7.0	76
14	Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma. <i>Laryngoscope</i> , 2017, 127, 1583-1588.	2.0	8
15	Harnessing the Immune System as a Therapeutic Tool in Virus-Associated Cancers. <i>JAMA Oncology</i> , 2017, 3, 106.	7.1	16
16	A phase I study of pazopanib in combination with escalating doses of 131I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine. <i>PLoS ONE</i> , 2017, 12, e0178325.	2.5	10
17	Ramucirumab (R) plus pembrolizumab (P) in treatment naive (R) and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4046-4046.	1.6	14
18	A phase I clinical trial of AZD1775 in combination with neoadjuvant weekly cisplatin and docetaxel in borderline resectable head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6034-6034.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Prognostic significance of performance status in patients with head and neck squamous cell carcinomas (HNSCC) receiving immune checkpoint monoclonal antibodies (ICmAB) in a single institution.. <i>Journal of Clinical Oncology</i> , 2017, 35, e17506-e17506.	1.6	0
20	Cisplatin and Etoposide Versus Carboplatin and Paclitaxel With Concurrent Radiotherapy for Stage III Non-Small-Cell Lung Cancer: An Analysis of Veterans Health Administration Data. <i>Journal of Clinical Oncology</i> , 2015, 33, 567-574.	1.6	114